AbbVie will gain a series of rare disease drugs, including Elaprase for Hunter syndrome, a genetic disorder, and Replagal, to treat Fabry disease. It also inherits experimental products, including lifitegrast for dry eye, and Premiplex for a potentially blinding eye disorder in infants. Premiplex could generate more than $1 billion annually if it reaches the market, said Jason Gerberry, an analyst at Leerink Partners.
thiis thread for idiots. * INSM is out of the recombinant technology business. They sold all their interests and all the people who knew anything about that business are gonzo. Including the guy they hired
I know you have been here for a long time and should know better to post misleading information like this.
Insmed will receive zero on anything regarding premiplex selling all rights to this last year.all rights.
insm got what...$11 million for premiplex? and now they're saying it's worth $1 billion annually??? I don't think lewis is that stupid. Something is going on behind the scenes with iPlex - what could it be?
Shire was "gifted" iPlex rights for ROP for the token sum of $11M because they will bear the cost of new manufacturing. Having a commercial supply will make it available for the already FDA-approved indication of short stature in 2018, along with any other potential indications that INSM can trial alone or with partners.